TP53 and cancer: The immune-, genomic alteration-, cell cycle-, and other classical cancer-related pathways, such as primary immunodeficiency, DNA mismatch repair, 3q29 CNV syndrome, cell cycle, and p53 signaling pathway, were mainly activated in the high-risk group.